Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02493361 · ClinicalTrials.gov registry record · Phase 2
Trial of pIL-12/MK-3475 in Metastatic Melanoma
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02493361 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 24 participants.
The verdict
NCT02493361, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a multicenter, Phase II, open-label, 42-patient single-arm trial of intratumoral pIL-12 electroporation (EP) in combination with pembrolizumab in patients with melanoma. Patients will be evaluated in 2 parts. Part A patients will be selected using a flow cytometric assay that quantifies intratumoral PD-1hiCD8+CTLA4+ "exhausted" lymphocytes in the tumor. Part B will enroll patients who have or are failing pembrolizumab at least 12 weeks after starting Programmed cell death protein 1 (PD-1) antibody alone or in combination, or, who have been selected using a flow cytometric assay that quantifies intratumoral PD-1hiCD8+CTLA4+ "exhausted" lymphocytes in the tumor.
Interventions
- DRUG Pembrolizumab
- DRUG pIL-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-08-17 |
| Est. Completion | 2020-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02493361
The ClinicalTrials.gov registry entry for NCT02493361 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02493361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02493361 about?
NCT02493361 is a clinical study titled "Trial of pIL-12/MK-3475 in Metastatic Melanoma". This is a multicenter, Phase II, open-label, 42-patient single-arm trial of intratumoral pIL-12 electroporation (EP) in combination with pembrolizumab in patients with melanoma. Patients will be evaluated in 2 parts. Part A patients will be selected using a flow cytometric assay that quantifies intr...
What is the current status of trial NCT02493361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-08-17. Estimated completion is 2020-03-02.
What interventions are being tested in trial NCT02493361?
The interventions under investigation include: Pembrolizumab (DRUG), pIL-12 (DRUG).
Who is sponsoring clinical trial NCT02493361?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.